The first step toward a national electronic system that will transform FDA?s ability to track the safety of drugs, biologics, and medical devices is up and running, according to a recent press release announcing the Mini-Sentinel Pilot project.
The first step toward a national electronic system that will transform FDA’s ability to track the safety of drugs, biologics, and medical devices is up and running, according to a recent press release announcing the Mini-Sentinel pilot project.
The Mini-Sentinel pilot project will facilitate the informed development and implementation of the larger fully operational Sentinel System. Through the Mini-Sentinel pilot, FDA will evaluate valid and reliable scientific methods, safety issues using existing electronic healthcare data systems, and the barriers and challenges to building a viable and accurate system of safety surveillance, according to the project’s Website.
The Mini-Sentinel system is designed to accommodate urgent FDA requests for information about medical product exposures and outcomes, and aims to post results relating exposure of a medical product to a health outcome within 30 days of completion of standard checks for accuracy.
FDA cautions that the presence of a drug, device, or biologic as a subject of Mini-Sentinel activity does not mean the agency has concluded there is a risk associated with it. The agency may have identified a potential safety issue, but not a causal relationship between the drug, device, or biologic and the named risk, according to the disclaimer on the project’s Website.
The Mini-Sentinel pilot project database took 2 years to develop, and it focuses on drugs, vaccines, other biologics, and medical devices. With 17 data partners across the United States, the database now includes data on nearly 100 million patients, 2.9 billion prescription drug dispensings, and 2.4 billion unique medical encounters, including 38 million acute inpatient hospital stays.
For more information, visit the Mini-Sentinel Website: http:/mini-sentinel.org/.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More